---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000107"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T22:54:59.248807+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance

## Summary
- Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.
- Purified Cortrophin Gel net revenues rose 93.8% to $101.9 million.
- Adjusted non-GAAP EBITDA of $59.6 million, up 69.8%.
- Raised 2025 total net revenue guidance to $854M-$873M and adjusted EPS to $7.37-$7.64.
- GAAP diluted EPS of $1.13 vs. net loss of $1.27 per share in prior year period.

## SEC filing metadata
- accession: 0001023024-25-000107
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/0001023024-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/ani-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000107
- JSON: https://secwatch.observer/filing/0001023024-25-000107.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.